International Journal of Current Science Research and Review
ISSN: 2581-8341
Volume 08 Issue 12 December 2025
DOI: 10.47191/ijcsrr/V8-i12-42, Impact Factor: 8.048
IJCSRR @ 2025
www.ijcsrr.org

Spatial Transcriptomics in Cancer Research: Methods and Applications

P. Kishore kumar[1*], K. Malikarjun Rao[2], Syed Mohiuddin Quadri[2], Bagadam Aparna[2], V. Uma Maheshwar rao[3]

[1*]M. Pharm. Ph.D. Associate Professor, Dept. of Pharmacology, CMR College of Pharmacy, Medchal, Hyderabad, India
[2]Student, Department of Pharm D, CMR College of Pharmacy, Medchal, Hyderabad, India
[3]M. Pharm. Ph.D. Principal, CMR College of Pharmacy, Medchal, Hyderabad, India

ABSTRACT: Spatial transcriptomics, which deals with tissue architecture in genetic investigation, is an innovative technique for examining cell heterogeneity and tissue organization. This review emphasizes major approaches, include spatially resolved transcriptome methods, immunohistochemistry as well as in situ hybridization, all of which permit the mapping of RNA molecules in their native tissue environment. These methods have proven essential in achieving our understanding of biological events such as tumor evolution, progression of cancer, and cancer tumor stem cell detection. Spatial transcriptomics, the study of patterns of gene expression in space, reveals the intricate nature of the tumor microenvironment (TME) and its effect on cancer biology. Although it delivers insight on the cellular connections that underlie disease, the significance of spatial transcriptomics in multiple organs has expanded.

Although its immense potential, there are still difficulties to be conquered, particularly within the areas of analysis of data, spatial resolution, and integration with other omics data. To be able to fully comprehend the complexities of tissues biology and ailments, this review additionally tackles future potential avenues, including the necessity for greater multiplexing, enhanced resolution, and the combination of functional genomics. With this synthesis, we intend provide an extensive summary of the state of spatial transcriptomics currently and demonstrate that it possesses the potential to improve precision medicine, cancer research, and our understanding of broader biology.

KEY WORDS: Cancer, Functional Genomics, Precision medicine, Spatial Transcriptomics, TME

INTRODUCTION

Spatial transcriptomics is a novel molecular approach that allows for the analysis of gene expression while preserving the spatial architecture of cells within a given tissue sample. Traditional RNA sequencing methods include homogenizing tissue, which removes that spatial information, but spatial transcriptomics enables scientists to observe how different cell types relate to one another in terms of their gene activity in situ (within the actual tissue context). This approach generates a rich high-resolution transcriptomic map of complex tissue with the simultaneous combination of histological imaging and RNA sequencing. This discipline has developed quickly from its foundation based on pharmaceuticals such as spatial barcoding, in situ hybridization, and laser microdissection, among others. These approaches allow for the precise localization of RNA molecules in discrete tissue slices giving the ability to decipher cellular function, tissue organisation and disease pathology with high spatial resolution [1].

The Significance of Tumor Heterogeneity

This technology plays important roles in study of tumor heterogeneity (the differences in cellular and molecular characteristics within a single tumor). Genetic mutations, epigenetic modifications, environmental factors, and interactions in the tumor microenvironment underpin this heterogeneity. Elucidating tumor heterogeneity is critical to developing better diagnostics, therapeutic modalities, and individualized medicine for cancer [2].

Identification of Tumor Subpopulations with Distinct Tumor Biology

Conventional bulk RNA sequencing yields an averaged gene expression profile of a given tumor, thereby concealing the composition of genetically and functionally distinct subclones within the mass of tumors.

Spatial transcriptomics does allow researchers to identify these subpopulations based on their unique gene expression patterns. Some of these subpopulations may have more aggressive, invasive or therapy resistant disease, thus identification is important for tailoring treatment [3].

International Journal of Current Science Research and Review
ISSN: 2581-8341
Volume 08 Issue 12 December 2025
DOI: 10.47191/ijcsrr/V8-i12-42, Impact Factor: 8.048
IJCSRR @ 2025
www.ijcsrr.org

Mapping the Tumor Microenvironment [TME]

The tumor microenvironment (TME) composes of cancer cells, immune cells, fibroblast, blood vessels and extracellular matrix (ECM) components. These components interact in a dynamic manner, impacting tumor development, metastasis, and the response to therapy. Spatial transcriptomics helps scientists map out these interactions and identify how different cellular components contribute to tumor growth.

For instance, T cells and macrophages can have important tumour-suppressing or -promoting roles in the immune response. Characterizing tumor-infiltrating immune cells in terms of their spatial distribution and functional states can help us to understand the mechanisms of immune evasion in the tumor microenvironment and, consequently, design new immunotherapies [4,5].

Personalized medicine and targeted therapies.

Historically, standard of care strategies for cancer treatment have been developed according to tumor type and stage. However, because tumors are heterogeneous, patients will respond differently to the same treatment.

So certain regions of a tumor might show high expression of drug-resistance genes, while others might be more sensitive to a given therapy. With targeted regional drug delivery, clinicians can improve the effectiveness of treatment and reduce side effects [6].

Overcoming Drug Resistance

Induction of drug resistance, wherein tumor cells adapt to therapeutic pressures, is arguably one of the most significant challenges facing effective cancer treatment.

Identifying potential pathways towards resistance is made easier with spatial transcriptomics, which can reveal changes in drug-transport mechanisms, rewired metabolic pathways, and activation of alternative signaling pathways.

Identifying resistant subpopulations allows researchers to create combination therapies that target both sensitive and resistant cells, decreasing the probability of relapse and improving long-term outcomes in a patient [7].

Advancing Early Cancer Detection

Molecules that can distinguish the tumor in early stages from the normal tissue are often present in an abnormal concentration. Spatial transcriptomics permits the detection of these subtle changes at an early localized level, allowing diagnosis and intervention. The ability to catch cancer at spectrums of early-stage tumors can dramatically enhance the odds of surviving since it allows treatment at an appropriate time and perhaps even more aggressively [8].

Brief Overview of Advancements

With the recent improvements in spatial transcriptomics resolution and scalability, there has been also increasing focus on the integration of spatial principles with other omics technologies. This has thus begun to bridge cleanly into the era of biomedical research and its applications in clinics.

1. High-Resolution and Single-Cell Spatial Transcriptomics

Advances in these techniques have pushed spatial resolution up to the single-cell level, which is much more accurate in the mapping of gene expression.

These include:

• 10x Genomics Visium: Spatial gene expression to near single-cell resolution that is popular with cancer and neuroscience research.
• Slide-seq and Slide-seqV2: With nanometer precision, DNA-barcoded beads are used to investigate tissue architecture.
• MERFISH (Multiplexed Error-Robust Fluorescence In Situ Hybridization): Fast, flexible, and absolutely reliable with spatially resolved single molecule imaging of thousands of genes in individual cells.

The above methods allow for a better understanding of intercellular communications and tissue organization down various biological contexts [9].

2. Integration with multiomics techniques

Spatial transcriptomics are now being integrated with other omics technologies like:

• Spatial proteomics (mapping protein expression at the spatial level)
• Epigenomics (the study of DNA modifications concerning the tissue)
• Metabolomics (the analysis of metabolic pathways in spatial domains)

International Journal of Current Science Research and Review
ISSN: 2581-8341
Volume 08 Issue 12 December 2025
DOI: 10.47191/ijcsrr/V8-i12-42, Impact Factor: 8.048
IJCSRR @ 2025
www.ijcsrr.org

An integration that thus offers a holistic picture of cellular function for enhanced disease modeling and biomarker study [10].

3. Application of AI and ML to Spatial Data Analysis

The generation of all the datasets from spatial transcriptomics is staggering. Thus, a computer's assistance is needed for data analysis. As such, machine learning and AI have been implemented to achieve the following objectives:

• Classify cell types by the location patterns of gene expression.
• Forecast the evolution of the disease through the identification of molecular signatures.
• Rationalize tissue architecture and deduce inter-cellular communication networks.

This again increases our possibilty of making sound decisions from the complex spatial transcriptomic datasets. [11]

4. Clinical Use Cases and Biomarker Identification

A number of spatial transcriptomics use cases are becoming apparent, particularly in cancer. The identification of spatially resolved biomarkers will change the landscape for cancer detection, patient prognosis, and treatment planning. For example, the sophisticated classification of breast cancer subtypes through RNA spatial transcriptomics have greatly improved the accuracy of breast cancer prognostic and therapeutic strategies. [12]

5. 3D Spatial Transcriptomics Overhaul

New approaches seek to add a third dimension to spatial transcriptomic analysis for a complete tissue structural view. 3D spatial transcriptomics allows researchers to analyze layered structures, like the brain and tumor-stroma interactions, in a more physiologically relevant way. [13]

METHODS IN SPATIAL TRANSCRIPTOMICS:

Spatial transcriptomics are effective methods for analysing gene expression while maintaining tissue's spatial environment. There are numerous approaches, each with special advantages and uses [14]. Here, we provide several classes of methods that either use spatial arrays of mRNA probes at predefined sites, scan the positions of cells before assessment, or record the locations of hybridized mRNA molecules in tissue. We go over the number and kinds of genes that can be profiled, the sizes of tissue areas that can be evaluated, and their spatial resolution. We address whether platform selection is influenced by tissue preservation and offer advice on whether particular platforms would be more appropriate for hypothesis testing or discovery screen [1].

- In situ hybridization
- Immunohistochemistry
- Spatially - resolved transcriptomics technologies (e.g. ST, Visium)
- Data analysis and integration methods

1. **In situ hybridization**:

In situ hybridisation (ISH) is a method used to identify particular nucleic acid sequences in cells or tissue samples. A potent spatial transcriptomics technique for determining target RNA location and abundance in individual cells is RNA in situ hybridization (RNA-ISH). This makes it possible to analyze tumor heterogeneity and expression localization, two things that transcriptome data analysis does not easily provide. Large volumes of data are produced by RNA-ISH studies, necessitating automated analysis techniques[15].

There are various types of ISH, including as fluorescent ISH, chromogenic ISH, radioactive ISH, and multiplexed ISH methods like RNAscope[16].

Primary Approaches for In Situ Hybridisation

a. The Chromogenic ISH: These offer a colorimetric signal detectable under light microscopy using enzyme- labeled probes. These are frequently employed in clinical diagnostics and gene expression analysis[17]. Chromogenic in situ hybridization, or CISH, is a technique that locates a particular DNA or RNA sequence in a tissue sample using a tagged complementary DNA or RNA strand[18].

b. The use of fluorescence FISH, or in situ hybridisation, is one type of in situ hybridisation.

uses fluorescently labelled probes to find high-resolution RNA or DNA sequences.

spatiotemporal transcriptomics, gene expression, and chromosomal analysis[19]. This method involves attaching a person's entire set of chromosomes to a glass slide and exposing it to a pure DNA probe that has been dyed fluorescently. Within the set of

International Journal of Current Science Research and Review
ISSN: 2581-8341
Volume 08 Issue 12 December 2025
DOI: 10.47191/ijcsrr/V8-i12-42, Impact Factor: 8.048
IJCSRR @ 2025
www.ijcsrr.org

chromosomes, the fluorescently labeled probe locates and attaches itself to its corresponding sequence. The chromosome and sub-chromosomal position where the fluorescent probe binds can be observed using a specialized microscope [20].
c. Multiplexed ISH: Branched DNA probes are used in this sophisticated ISH technique to improve signal detection. beneficial for gene expression investigation at single-cell resolution [21].

2. Immunohistochemistry:
Immunohistochemistry (IHC) is frequently combined with spatial transcriptomics to connect protein expression with gene expression in tissue slices. It validates mRNA results at the protein level, improving the understanding of spatial gene expression. Although immunotherapy has revolutionized the field of cancer treatments, it only benefits a limited percentage of tumor types, necessitating the use of a companion diagnostic test. The only approved companion diagnostics are polymerase chain reaction (PCR) for microsatellite instability (MSI), immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) or mismatch repair (MMR), and others are being considered. IHC's spatial information and RNA expression profiling's quantitative information could be used to provide the ideal companion diagnostic test [22].

Techniques for Combining Spatial Transcriptomics with IHC
a. Indexing-Based Co-Detection (CODEX): A multiplexed imaging technique that simultaneously detects proteins and transcriptomes using DNA-conjugated antibodies[23].
b. IF-ST: Integrating spatially barcoded transcriptomics, like 10x Genomics Visium, with antibody-based immunofluorescence [24].
c. Spatial Multi-Omics using RNA- seq and IHC: Analyse patterns of mRNA and protein expression using spatial transcriptomic analysis on tissue slices labelled with IHC [25].

3. Spatially - resolved transcriptomics technologies:
Precise genome-wide mRNA expression analysis inside tissue slices is now possible thanks to spatially resolved transcriptomics. The effectiveness of techniques that target the polyA tails of mRNA depends on the availability of high-quality RNA specimens. Furthermore, a thorough sample screening procedure is necessary to improve the likelihood of collecting high-quality data due to the high cost of the spatial resolved transcriptomics assays that are currently on the market. Indeed, sample processing, storage, and/or intrinsic variables can cause significant variability in the upfront analysis of RNA quality. mRNA recovery from fresh frozen specimens with moderate to low RNA quality can be enhanced using the RNA-Rescue Spatial Transcriptomics (RRST) method [26].
to technologies that allow for the high-resolution mapping of mRNA within tissues by maintaining spatial context while analysing gene expression. Techniques fall into three categories: multi-omics, sequencing-based, and imaging-based
a. Spatial Transcriptomics Based on Imaging: These techniques visualise transcripts at the subcellular level using in situ sequencing or in situ hybridisation (ISH).
MERFISH (In Situ Hybridisation of Multiplexed Error-Robust Fluorescence) detects hundreds of RNA species with excellent spatial resolution using barcoded probes [27].
b. Spatial Transcriptomics Using Sequencing: Both bead-based and barcoded arrays are used in these techniques to separate mRNA and record spatial information. Barcoded spatial arrays are used in spatial transcriptomics (ST) to profile gene expression in tissue samples [1].
c. Spatial Multi-Omics Transcriptomics: These techniques combine proteomics, epigenomics, or histology with spatial transcriptomics [28]. With the ability to jointly examine numerous data modalities such as the transcriptome, epigenome, proteome, and metabolome in parallel or even the same tissue segment, spatial multi-omic studies have become a viable method for thoroughly analyzing cells in tissues [29].

4. Data analysis and integration methods:
High-dimensional data generated by spatial transcriptomics need sophisticated computational techniques for integration and interpretation. Preprocessing, clustering, geographical mapping, multimodal integration, and machine learning techniques are some of these techniques.
a. Normalisation and preprocessing: Spatial transcriptomics data are subjected to batch correction, normalisation, and quality control prior to analysis in order to eliminate technological biases.

International Journal of Current Science Research and Review
ISSN: 2581-8341
Volume 08 Issue 12 December 2025
DOI: 10.47191/ijcsrr/V8-i12-42, Impact Factor: 8.048
IJCSRR @ 2025
www.ijcsrr.org

Important Techniques:
Seurat is a popular R program for processing data from single cells and spatial transcriptomics.
A statistical technique for identifying genes that vary in space is called SPARK.

b. Spatial Domain Identification and Clustering: Define spatial domains and get insight into tissue architecture by identifying tissue regions with certain gene expression patterns.
Important Techniques:
A Bayesian model to improve spatial resolution is called BayesSpace.
STAGATE: Clusters spatial transcriptomics data using graph neural networks[30].

c. Mapping Gene Expression in Space: Tissue-specific indicators and regionally variable genes are found by spatial gene expression mapping.
Important Techniques:
Identification of spatially variable genes using the Spatial DE-model.
Trendsceek is a probabilistic approach for identifying tissue-wide trends in gene expression.

d. Combination with scRNA-seq (single-cell RNA sequencing):
Reconstructing spatial tissue organisation and identifying cell types are facilitated by the combination of scRNA-seq and spatial transcriptomics.
Important Techniques:
Seurat v3/v4: Combines single-cell transcriptomics data with geographical data.
Single-cell data can be mapped onto spatial datasets using the Tangram model.

e. Deep Learning and Machine Learning Methods: From spatial transcriptomics data, AI-based methods help predict cell types, tissue architecture, and disease development.
Important Techniques:
ST-Net is a deep learning method for determining patterns of spatial gene expression.
A neural network model for spatial clustering based on graphs is called GraphST [31].

APPLICATIONS IN CANCER RESEARCH

Applications of spatial transcriptomics in cancer research have been numerous such as establishing spatially regulated biomarkers, recognizing tumor-stroma crosstalk, and revealing intra-tumoral heterogeneity. Our understanding of tumor genesis, progression, and resistance to treatment, in addition to the development of personalized and targeted treatment strategies, will all be significantly enhanced by the ability to investigate the spatial dynamics of gene expression within tumors [32].

LUNG CANCER

In the multifaceted disease of lung cancer, the tumor microenvironment is crucial, and macrophages have a significant contribution to the disease's progression. TAMs, in particular, may perform a couple of functions: they can suppress tumors by promoting inflammation and cytotoxically assaulting cancer cells, but also promoting tumors by suppressing the body's immune system, promoting angiogenesis, and aiding in tissue remodeling [33].
Anti-tumor immunity is critically controlled by tumor-associated macrophages (TAMs), one of the most prominent immune cells in the tumor microenvironment (TME). It remains unknown in which processes regulate their abundance in the TME [34].
According to Larroquette et al. [35]. NanoString GeoMx was applied to conduct a geographical evaluation of 78 in situ transcripts from 16 tumor tissues. The results revealed that the distance from tumor cells directly impacts the prognostic effect of TAMs in NSCLC. Furthermore, the three genes found to be highly up-regulated in tumors with high levels of TAM infiltration—CD27, CCL5, and ITGAM—may be feasible targets for immunotherapy. In addition, TME analysis employing digital spatial profiling (DSP) and multiplex immunohistochemistry (mIHC) has been identified in samples of NSCLC patients upon immune checkpoint inhibitor (ICI) treatment [34].

International Journal of Current Science Research and Review
ISSN: 2581-8341
Volume 08 Issue 12 December 2025
DOI: 10.47191/ijcsrr/V8-i12-42, Impact Factor: 8.048
IJCSRR @ 2025
www.ijcsrr.org

BREAST CANCER

Breast cancer kill more than 100 people every day in the United States alone, and victims suffer drastically from the very complex therapies for the disease. Breast cancer remains to be a major threat to public health. Human epidermal growth factor receptor 2 (HER2) expression is enhanced by tumor cells in HER2-positive tumors, one of the subtypes of breast cancer [36].

Novel therapeutic targets for the therapy of breast cancer have been identified employing ST technology, enabling an intricate delineation of the genotype, phenotype, and states of activity or inactivity of different immune cell forms. In contrast to other breast cancer subtypes, claudin-low breast cancer can be distinguished by an enormous immune cell infiltration, includes an elevated number of B cells, T cells, NK cells, macrophages, and neutrophils. Experimental investigations have discovered, however, that a substantial number of patients are resilient to immune checkpoint interventions despite the face of extensive lymphocytic infiltration. Multiple variants of various immune checkpoint genes, that include CD276 and Neuropilin-1 (NPR1), in addition to CD274, contribute to immunosuppressive mechanisms and impede the potency of PD-L1 inhibitory therapies [37].

COLORECTAL CANCER

Globally, colorectal cancer (CRC) remains the second most prevalent type of cancer in terms of mortality. Mutations that target oncogenes, tumor suppressor genes, and genes that regulate pathways that repair DNA exist in the colonic and rectal epithelial tissues, contributing to these kinds of cancer [38]. Implementing multiomics procedures, such as spatial transcriptome (ST) and scRNA-seq, to fully evaluate the relationship between immune cells and tumors in colorectal cancer. The contribution of tumor cells with improved nucleotide metabolism (NUhighepi), a formerly undetected site associated with colorectal cancer tissues, has attracted particular scrutiny from them and concluded that the TME altered the biological action of tumor-resident NUhighepi, making them more pro-tumor. For the very first time, careful investigation further demonstrated a close spot between tumor-associated fibrogenesis and NUhighepi. Results verified that the association promotes malignant transformation by triggering pro-tumor signaling cascades in fibroblasts, involving the COL1A1/COL1A2_ITGB1 axis, this ultimately elevates the aggressive phenotype of NUhighepi. thereby, an ideal strategy for colorectal cancer intervention may be given by these cellular communications [39].

TUMOR EVOLUTION

Genetic, epigenetic, and environmental factors together contribute an important role in the dynamic process of tumor evolution, resulting in the development of different populations of cancerous cells [40]. In accordance to the clonal evolution speculation, carcinomas evolve from a single progenitor cell that transforms as time passes to generate subclonal populations with varying levdegrees of fitness and survival advantage [41].

Genetic instability promotes intratumor heterogeneity, triggering treatment resistance and the growing severity of the disease [42]. Moreover, the evolutionary trajectory of tumor cells is influenced by selective factors such as immune surveillance and therapy, that stimulates phenotypic plasticity and adaptation mechanisms [43].

TUMOR PROGRESSION

Localized growth is the primary phase in tumor progression, is then followed by invasion and metastasis [44]. Genomic instability is a major force underlying progression, accelerating up anomalies in chromosomes and mutations that generate aggressive cancer phenotypes [42].

The epithelial-mesenchymal transition (EMT), that offers cancer cells the capability to spread and infest, is key to metastasis [45]. Local invasion, penetration into circulation, bloodstream survival, extravasation, and colonizing at distant sites were every aspect of the metastatic cascade, and is modulated by molecular pathways such TGF-β signaling and PI3K/Akt [44].

Developing precision oncology strategies, particularly design targeted medications based upon tumor genomic profiles, becomes possible through an understanding of tumor progression. Employing circulating tumor DNA (ctDNA), liquid biopsies enable continuous surveillance of tumor development as well as therapy response [46]. Immunocheckpoint inhibitors, especially PD-1/PD-L1, have been demonstrated to significantly enhance patient outcomes, and immunotherapy has emerged as an effective strategy against immune evasion mechanisms [47]. In addition, implementing combination therapies for dealing with drug resistance involves a comprehension of resistance mechanisms, like epigenetic modifications and adaptive mutational landscapes [48].

International Journal of Current Science Research and Review
ISSN: 2581-8341
Volume 08 Issue 12 December 2025
DOI: 10.47191/ijcsrr/V8-i12-42, Impact Factor: 8.048
IJCSRR @ 2025
www.ijcsrr.org

CANCER STEM CELL IDENTIFICATION

cancer stem cells (CSCs) has become crucial for cancer research considering that they are a subpopulation of tumor cells which possesses the ability to self-renew, differentiate, and stimulate the development of tumors [49]. The surface indicators comprising CD133, CD44, and ALDH1, are frequently arise in numerous kinds of carcinomas, such as glioblastomas, the breasts, and the colon, are applied for recognizing CSCs [50]. In order to assess the cells' ability towards self-renewal and differentiation, functional assessments like sphere formation and also side population analysis are carried out [51]. In spite of the aid of innovative techniques like flow cytometry and single-cell RNA sequencing, CSC recognition and profiling have been enhanced further, revealing a comprehensive perspective on tumor heterogeneity as well as therapeutic tolerance [50]. With regard to its frequent role in resistant to therapy and metastases, a grasp of CSCs proves essential for the further study of customized therapies [52]. Further investigations into CSCs may result to favorable patient outcomes and more robust cancer therapies [53].

IMMUNE CELL INFILTRATION AND INTERACTION

A significant influence in the onset of cancer and its implications of victims is the infiltration of immune cells within tumors. Investigations indicate the fact that the existence of greater numbers of immune cells in tumors has been associated to more favorable survival rates that may forecast how effectively immunotherapies operate [54]. Tumor expansion advancement and therapeutic responses are significantly impacted based on unpredictable interactions among malignant cells and assaulting immune cell types [55]. A better comprehension of the tumor-immune interfacing has become feasible owing to modern spatial analysis instruments which enable visual inspection of these connections at the single-cell differentiation level [56]. It is necessary to learn about these complicated connections for the purpose to generate cancer immunotherapies which function well and optimize clinical efficacy [55].

TUMOR MICROENVIRONMENT ANALYSIS

A tumor's cells that are not malignant along with additional aspects, like chemicals that they generate and discharge, comprise the tumor microenvironment (TME). Tumor initiate, development, metastases, as well as effectiveness of therapy all are greatly impacted through interactions among the tumor cells and the TME [57]. The TME tends to be reviewed to detect molecules that support in the expansion and development of cancerous cells, notably cancer stem cells. Throughout treatment for cancer, addressing and altering TME aspects might help in the oversight of tumors while strengthening the outcomes of patients [58,59]. Considering the TME remains critical in establishing new approaches for the therapeutic management of cancers [60].

FUTURE AVENUES AND OBSTACLES

INTEGRATION WITH OTHER OMICS TECHNOLOGIES

Despite it permits an intimate knowledge of biological mechanisms, integrating numerous omics technologies—such as transcriptomics, proteomics, metabolomics, along with genomics—presents substantial obstacles and potential opportunities [61]. The multifaceted nature and elevated the dimensionality of information pose a significant challenge, demanding specialized computing algorithms enabling accurate handling and understanding of the enormous quantities of data processed [62]. Meanwhile, the advancement of robust de-noising techniques is necessary to ensure the accuracy of data and reliability owing to the noise and variability found in single-cell data [63]. Compatibility amongst diverse omics databases remains necessary owing to different structures for data could render integration and analysis complicated [64]. In addition, it might be tough to analyze and evaluate integrated data, especially whenever sophisticated approaches like neural networks are utilized. This feature emphasizes the necessity for approaches that provide distinct biological insights. With the aim to enhance our understanding of complicated biological systems and progress the incorporation of omics technology, these challenges need to be overcome [65].

CLINICAL TRANSLATION AND PERSONALIZED MEDICINE

Contemporary medical care stands at the leading edge of personalized healthcare and clinical translation, offering customized therapies based on each individual's specific genetic profile. Yet there are additionally several kinds of difficulties that hinder their wide choose [66]. Data security and patient confidentiality become crucial concerns once genomic data is incorporated into clinical settings. Upholding trust and abiding to ethical standards requires that genetic information remain protected from unauthorized disclosure [67]. despite the overall expenditure for genetic sequencing has dropped, accessible disparities still exist, as well as

International Journal of Current Science Research and Review
ISSN: 2581-8341
Volume 08 Issue 12 December 2025
DOI: 10.47191/ijcsrr/V8-i12-42, Impact Factor: 8.048
IJCSRR @ 2025
www.ijcsrr.org

financial constraints might hinder certain individuals from acquiring specific medicines, that might end up in disproportionate healthcare outcomes [68]. Personalized healthcare is emerging quicker beyond established regulatory frameworks. It serves as crucial to establish regulations that safeguard the safety of patients without restricting innovation. In addition, consent-related ethical issues ought to be addressed, especially when it pertains to the utilization of genetic information for research [69].

DATA SHARING AND COLLABORATION

To contribute enhance innovation and study, collaboration and sharing of data are necessary, however they additionally carry an array of interesting challenges and possibilities. With establishing international norms, data sharing practices may become standard, facilitating easier collaboration. The requirement for a global agreement is emphasized through efforts like the European Health Information Space, that's strive to improve transfer of data and the beneficial effects of AI in healthcare [70]. Expanding innovations, including data secure environments may offer organizations secure places for working cooperatively on confidential data without affecting privacy. These configurations protect the confidentiality of the original data while permitting the evaluation of combined datasets [71]. The broad spectrum of spatial transcriptomics systems and approaches generates a variety of data formats and quality standards. Standardized procedures and data formats need to be developed for the purpose to ensure uniformity and reproducibility across investigations [1]. Spatial transcriptomics analysis is a highly computational but expensive procedure. With the goal to effectively deal with and evaluate large data sets, collaborations ought to focus on developing and distributing scalable computational instruments and equipment [72]. The impact of spatial transcriptomics in study of cancer is going to be strengthened by resolving these challenges through advances in technology and collaborative efforts, this will culminate in more precise diagnoses and targeted therapies [73].

CONCLUSION

According to studies pertaining to cancer, spatial transcriptomics has grown into a revolutionary method which provides significant insights into tumor microenvironment (TME), tumor heterogeneity, and the ongoing events that enable tumor growth and progression. By incorporating tools like immunohistochemistry, in situ hybridization, and precise spatially resolved transcriptomics systems, investigators have the ability to examine cancer at a never-before-seen extent of information, detecting significant biomarkers and biological markers associated with tumor effects. Applications in an assortment of tumor types, that include the detection of cancer stem cells and investigating the possibility of immune cell infiltration, have paved the door to more customized and precise curative strategies. Nevertheless there currently remains various kinds of obstacles. A greater comprehension of tumor physiology could possibly be achieved by integrating spatial transcriptomics with additional omic methods including proteomics and genomes. Addressing challenges in integrating data, sharing, and collaboration among research networks is required to progress towards clinical translation along with personalized therapy. Accessing the complete potential of spatial transcriptomics in tumor identification and therapeutic sessions requires multidisciplinary teams and advances in technology as the field progresses.

REFERENCES

1. Williams CG, Lee HJ, Asatsuma T, Vento-Tormo R, Haque A. An introduction to spatial transcriptomics for biomedical research. Genome Medicine. 2022a Jun 27;14(1).
2. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010 Jan;1805(1):105-17. doi: 10.1016/j.bbcan.2009.11.002. Epub 2009 Nov 18. PMID: 19931353; PMCID: PMC2814927.
3. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8. doi: 10.1073/pnas.0610117104. Epub 2007 Jan 8. PMID: 17210912; PMCID: PMC1783424.
4. Wang Y, Wang Y, Liu B, Gao X, Li Y, Li F, Zhou H. Mapping the tumor microenvironment in clear cell renal carcinoma by single-cell transcriptome analysis. Front Genet. 2023 Jul 18;14:1207233. doi: 10.3389/fgene.2023.1207233. PMID: 37533434; PMCID: PMC10392130.
5. Grasset EM, Deshpande A, Lee JW, Cho Y, Shin SM, Coyne EM, Hernandez A, Yuan X, Zhang Z, Cimino-Mathews A, Ewald AJ, Ho WJ. Mapping the breast tumor microenvironment: proximity analysis reveals spatial relationships between macrophage subtypes and metastasis-initiating cancer cells. Oncogene. 2024 Sep;43(39):2927-2937. doi: 10.1038/s41388-024-03127-9. Epub 2024 Aug 20. PMID: 39164522.

International Journal of Current Science Research and Review
ISSN: 2581-8341
Volume 08 Issue 12 December 2025
DOI: 10.47191/ijcsrr/V8-i12-42, Impact Factor: 8.048
IJCSRR @ 2025
www.ijcsrr.org

6. Singh D, Dhiman VK, Pandey M, Dhiman VK, Sharma A, Pandey H, et al. Personalized medicine: An alternative for Cancer Treatment. Cancer Treatment and Research Communications [Internet]. 2024 Dec 20;48(42):100860. Available from: https://www.sciencedirect.com/science/article/pii/S2468294224000728
7. Madukwe JC. Overcoming drug resistance in cancer. Cell. 2023 Apr;186(8):1515–6.
8. Shaymaa AlWaheidi. Promoting cancer prevention and early diagnosis in the occupied Palestinian territory. Journal of Cancer Policy. 2022 Dec 6;35:100373–3.
9. Schott M, León-Periñán D, Splendiani E, Strenger L, Jan Robin Licha, Tancredi Massimo Pentimalli, et al. Open-ST: High-resolution spatial transcriptomics in 3D. Cell. 2024 Jun 1;39(22).
10. Heo YJ, Hwa C, Lee GH, Park JM, An JY. Integrative Multi-Omics Approaches in Cancer Research: From Biological Networks to Clinical Subtypes. Mol Cells. 2021 Jul 31;44(7):433-443. doi: 10.14348/molcells.2021.0042. PMID: 34238766; PMCID: PMC8334347.
11. Maurya R, Chug I, Vudatha V, Palma AM. Applications of spatial transcriptomics and artificial intelligence to develop integrated management of pancreatic cancer. Adv Cancer Res. 2024;163:107-136. doi: 10.1016/bs.acr.2024.06.007. Epub 2024 Jul 9. PMID: 39271261.
12. Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024 Mar 28;187(7):1617-1635. doi: 10.1016/j.cell.2024.02.041. PMID: 38552610; PMCID: PMC7616034.
13. Carnevali F, Forciniti S, Onesto V, Siciliano AC, Iuele H, Grasso G, et al. Advancements in Cancer Research: 3D Models, Single-Cell, and Live-Cell Techniques for Better Insights. Advanced Therapeutics. 2024 Nov 9;12(22).
14. Ståhl, P. L., Salmén, F., Vickovic, S., Lundmark, A., Navarro, J. F., Magnusson, J., Giacomello, S., Asp, M., Westholm, J. O., Huss, M., Mollbrink, A., Linnarsson, S., Codeluppi, S., Borg, Å., Pontén, F., Costea, P. I., Sahlén, P., Mulder, J., Bergmann, O., … Frisén, J. (2016). Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. *Science (New York, N.Y.)*, *353*(6294), 78–82. https://doi.org/10.1126/science.aaf2403
15. Jamalzadeh, S., Häkkinen, A., Andersson, N., Huhtinen, K., Laury, A., Hietanen, S., Hynninen, J., Oikkonen, J., Carpén, O., Virtanen, A., & Hautaniemi, S. (2022). QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability. *Laboratory Investigation; a Journal of Technical Methods and Pathology*, *102*(7), 753–761. https://doi.org/10.1038/s41374-022-00743-5
16. Wilkinson, D. G. (Ed.). (1998). *In situ hybridization: A Practical Approach*. Oxford University PressOxford. https://doi.org/10.1093/oso/9780199636594.001.0001
17. Schaeren-Wiemers, N., & Gerfin-Moser, A. (1993). A single protocol to detect transcripts of various types and expression levels in neural tissue and cultured cells: in situ hybridization using digoxigenin-labelled cRNA probes. *Histochemistry*, *100*(6), 431–440. https://doi.org/10.1007/bf00267823
18. Madrid MA, Lo RW. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Research. 2004 Jul 29;6(5).
19. Raj, A., van den Bogaard, P., Rifkin, S. A., van Oudenaarden, A., & Tyagi, S. (2008). Imaging individual mRNA molecules using multiple singly labeled probes. *Nature Methods*, *5*(10), 877–879. https://doi.org/10.1038/nmeth.1253
20. Shakoori AR. Fluorescence In Situ Hybridization (FISH) and Its Applications. Chromosome Structure and Aberrations [Internet]. 2017 Feb 10;1(1):343–67. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7122835/
21. Wang, F., Flanagan, J., Su, N., Wang, L.-C., Bui, S., Nielson, A., Wu, X., Vo, H.-T., Ma, X.-J., & Luo, Y. (2012). RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. *The Journal of Molecular Diagnostics: JMD*, *14*(1), 22–29. https://doi.org/10.1016/j.jmoldx.2011.08.002
22. Vathiotis, I. A., Yang, Z., Reeves, J., Toki, M., Aung, T. N., Wong, P. F., Kluger, H., Syrigos, K. N., Warren, S., & Rimm, D. L. (2021). Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. *Npj Precision Oncology*, *5*(1), 1–6. https://doi.org/10.1038/s41698-021-00184-1
23. Goltsev, Y., Samusik, N., Kennedy-Darling, J., Bhate, S., Hale, M., Vazquez, G., Black, S., & Nolan, G. P. (2018). Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. *Cell*, *174*(4), 968-981.e15. https://doi.org/10.1016/j.cell.2018.07.010

24. Maniatis, S., Äijö, T., Vickovic, S., Braine, C., Kang, K., Mollbrink, A., Fagegaltier, D., Andrusivová, Ž., Saarenpää, S., Saiz-Castro, G., Cuevas, M., Watters, A., Lundeberg, J., Bonneau, R., & Phatnani, H. (2019). Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. *Science (New York, N.Y.)*, *364*(6435), 89–93. https://doi.org/10.1126/science.aav9776
25. Jackson, H. W., Fischer, J. R., Zanotelli, V. R. T., Ali, H. R., Mechera, R., Soysal, S. D., Moch, H., Muenst, S., Varga, Z., Weber, W. P., & Bodenmiller, B. (2020). The single-cell pathology landscape of breast cancer. *Nature*, *578*(7796), 615–620. https://doi.org/10.1038/s41586-019-1876-x
26. Mirzazadeh R, Andrusivova Z, Larsson L, Newton PT, Galicia LA, Abalo XM, et al. Spatially resolved transcriptomic profiling of degraded and challenging fresh frozen samples. Nature Communications [Internet]. 2023 Jan 31;14(1):509. Available from: https://www.nature.com/articles/s41467-023-36071-5
27. Chen, K. H., Boettiger, A. N., Moffitt, J. R., Wang, S., & Zhuang, X. (2015). RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. *Science (New York, N.Y.)*, *348*(6233), aaa6090. https://doi.org/10.1126/science.aaa6090
28. Rodriques, S. G., Stickels, R. R., Goeva, A., Martin, C. A., Murray, E., Vanderburg, C. R., Welch, J., Chen, L. M., Chen, F., & Macosko, E. Z. (2019). Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution. *Science (New York, N.Y.)*, *363*(6434), 1463–1467. https://doi.org/10.1126/science.aaw1219
29. Kiessling, P., & Kuppe, C. (2024). Spatial multi-omics: novel tools to study the complexity of cardiovascular diseases. *Genome Medicine*, *16*(1). https://doi.org/10.1186/s13073-024-01282-y
30. Zhao, E., Stone, M. R., Ren, X., Guenthoer, J., Smythe, K. S., Pulliam, T., Williams, S. R., Uytingco, C. R., Taylor, S. E. B., Nghiem, P., Bielas, J. H., & Gottardo, R. (2021). Spatial transcriptomics at subspot resolution with BayesSpace. *Nature Biotechnology*, *39*(11), 1375–1384. https://doi.org/10.1038/s41587-021-00935-2
31. Svensson, V., Teichmann, S. A., & Stegle, O. (2018). SpatialDE: identification of spatially variable genes. *Nature Methods*, *15*(5), 343–346. https://doi.org/10.1038/nmeth.4636
32. Jin Y, Zuo Y, Li G, Liu W, Pan Y, Fan T, et al. Advances in spatial transcriptomics and its applications in cancer research. Molecular Cancer. 2024 Jun 20;23(1).
33. De Zuani M, Xue H, Park JS, Dentro SC, Seferbekova Z, Tessier J, et al. Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nature Communications [Internet]. 2024 May 23;15(1):4388. Available from: https://www.nature.com/articles/s41467-024-48700-8
34. Wang W, Chu L, Li H, Zhang MJ, Dang K, Gao CY, et al. Spatial transcriptomics: recent developments and insights in respiratory research. Military Medical Research. 2023 Aug 17;10(1).
35. Larroquette M, Guegan JP, Besse B, Cousin S, Brunet M, Le Moulec S, et al. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. Journal for ImmunoTherapy of Cancer. 2022 May;10(5):e003890.
36. Andersson A, Larsson L, Stenbeck L, Salmén F, Ehinger A, Wu SZ, et al. Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. Nature Communications. 2021 Oct 14;12(1).
37. Zhang Y, Gong S, Liu X. Spatial transcriptomics: a new frontier in accurate localization of breast cancer diagnosis and treatment. Frontiers in Immunology. 2024 Oct 8;15.
38. Alzahrani S, Al Doghaither H, Al-Ghafari A. General insight into cancer: An overview of colorectal cancer (Review). Molecular and Clinical Oncology. 2021 Nov 1;15(6).
39. Liu J, Li H, Wang L, Wang S, Tang Q. Spatial transcriptome and single-cell reveal the role of nucleotide metabolism in colorectal cancer progression and tumor microenvironment. Journal of Translational Medicine. 2024 Jul 29;22(1).
40. Nowell P. The clonal evolution of tumor cell populations. Science. 1976 Oct 1;194(4260):23–8.
41. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. New England Journal of Medicine. 2012 Mar 8;366(10):883–92.
42. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic Instability — an Evolving Hallmark of Cancer. Nature Reviews Molecular Cell Biology. 2010 Mar;11(3):220–8.
43. Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next Generation. Cell. 2011 Mar;144(5):646–74.

44. Valastyan S, Weinberg Robert A. Tumor Metastasis: Molecular Insights and Evolving Paradigms. Cell. 2011 Oct;147(2):275–92.
45. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-Mesenchymal Transitions in Development and Disease. Cell. 2009 Nov;139(5):871–90.
46. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer. 2017 Apr 1;17(4):223–38.
47. Sharma P, Allison JP. The future of immune checkpoint therapy. Science [Internet]. 2015 Apr 2;348(6230):56–61. Available from: https://www.science.org/doi/10.1126/science.aaa8172
48. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer [Internet]. 2013 Oct 1;13(10):714–26. Available from: https://www.nature.com/articles/nrc3599.pdf
49. Batlle E, Clevers H. Cancer stem cells revisited. Nature medicine. 2017;23(10):1124–34.
50. Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, et al. Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Frontiers in Immunology [Internet]. 2020 Aug 7;11(1280). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426526/
51. Lathia JD, Liu H. Overview of Cancer Stem Cells and Stemness for Community Oncologists. Targeted Oncology. 2017 Jun 30;12(4):387–99.
52. Biserova K, Jakovlevs A, Uljanovs R, Strumfa I. Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma. Cells. 2021 Mar 11;10(3):621.
53. Gatenby RA, Zhang J, Brown JS. First Strike–Second Strike Strategies in Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction. Zenodo (CERN European Organization for Nuclear Research). 2019 Jul 10;66(19).
54. Melssen MM, Sheybani ND, Slingluff CL, Slingluff CL. Barriers to immune cell infiltration in tumors. Journal for ImmunoTherapy of Cancer [Internet]. 2023 Apr 1 [cited 2023 Nov 27];11(4):e006401–1. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124321/
55. Maffuid K, Cao Y. Decoding the Complexity of Immune–Cancer Cell Interactions: Empowering the Future of Cancer Immunotherapy. Cancers. 2023 Aug 21;15(16):4188–8.
56. Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, et al. Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology [Internet]. 2023 Aug 1 [cited 2024 Mar 3];260(5):514–32. Available from: https://pubmed.ncbi.nlm.nih.gov/37608771/
57. Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacology & Therapeutics [Internet]. 2020 Nov 28;221(107753):107753. Available from: https://www.sciencedirect.com/science/article/pii/S0163725820302849
58. Arneth B. Tumor Microenvironment. Medicina. 2019 Dec 30;56(1):15.
59. Cigir Biray Avci, Bakiye Goker Bagca, Masoud Nikanfar, Takanlou LS, Takanlou MS, Alireza Nourazarian. Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications. Frontiers in Pharmacology. 2024 Nov 12;15.
60. Farc O, Cristea V. An overview of the tumor microenvironment, from cells to complex networks (Review). Experimental and Therapeutic Medicine. 2020 Nov 26;21(1).
61. Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nature Reviews Genetics [Internet]. 2018 Feb 26;19(5):299–310. Available from: https://www.nature.com/articles/nrg.2018.4
62. Gidey F, Awono C. High Dimensional Data Visualization: Advances and Challenges. International Journal of Computer Applications. 2017 Mar 15;162(10):23–7.
63. Aparicio L, Bordyuh M, Blumberg AJ, Rabadan R. A Random Matrix Theory Approach to Denoise Single-Cell Data. Patterns. 2020 Jun;1(3):100035.
64. Vahabi N, Michailidis G. Unsupervised Multi-Omics Data Integration Methods: A Comprehensive Review. Frontiers in Genetics. 2022 Mar 22;13.
65. Elmarakeby HA, Hwang J, Arafeh R, Crowdis J, Gang S, Liu D, et al. Biologically informed deep neural network for prostate cancer discovery. Nature [Internet]. 2021 Oct 1;598(7880):348–52. Available from:

https://www.nature.com/articles/s41586-021-03922-4
66. Shaaban S, Ji Y. Challenges of Clinical Pharmacogenomics Implementation in the Era of Precision Medicine. Medical Research Archives. 2024;12(11).
67. Vavekanand R. Data Security and Privacy in Genomics Research: A Comparative Analysis to Protect Confidentiality. Studies in Medical and Health Sciences [Internet]. 2024 May 11;1(1):23–31. Available from: https://sabapub.com/index.php/SMHS/article/view/1158
68. Ward MM. Personalized Therapeutics: A Potential Threat to Health Equity. Journal of General Internal Medicine. 2012 Feb 7;27(7):868–70.
69. Patel S, Slavin C, Rao RR. Ethical Considerations in Personalized Medicine. Ethics in Biology, Engineering and Medicine: An International Journal. 2020;11(1):89–93.
70. Bernasconi L, Şen S, Angerame L, Balyegisawa AP, Hong Yew Hui D, Hotter M, et al. Legal and ethical framework for global health information and biospecimen exchange - an international perspective. BMC Medical Ethics. 2020 Jan 21;21(1).
71. None Santoshkumar Anchoori. Designing Privacy-Preserving Data Collaboration Architectures in Modern AdTech. International Journal of Scientific Research in Computer Science Engineering and Information Technology. 2024 Dec 7;10(6):1370–81.
72. Atta L, Fan J. Computational challenges and opportunities in spatially resolved transcriptomic data analysis. Nature Communications. 2021 Sep 6;12(1).
73. Maciejewski K, Czerwinska P. Scoping Review: Methods and Applications of Spatial Transcriptomics in Tumor Research. Cancers. 2024 Sep 6;16(17):3100.

Cite this Article: kumar, P.K., Rao, K.M., Quadri, S.M., Bagadam A., Maheshwar rao, V.U. (2025). Spatial Transcriptomics in Cancer Research: Methods and Applications. International Journal of Current Science Research and Review, 8(12), pp. 6304-6315. DOI: https://doi.org/10.47191/ijcsrr/V8-i12-42